Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 18/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 18/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 18/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 18/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 18/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 17/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 17/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.72 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.72 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | LTA4H | P09960 | 1/20 | 0.72 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31203555 | 1.00 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL14135053 | 1.00 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL28608420 | 1.00 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| Hydrochloric Acid SCHEMBL8750137 | 0.98 | HDAC6 (0.70) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| Hydrochloric Acid SCHEMBL827279 | 0.98 | HDAC6 (0.70) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL13973103 | 0.98 | HDAC6 (0.69) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| Hydrochloric Acid SCHEMBL28515049 | 0.96 | HDAC6 (0.67) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL22661265 | 0.94 | HDAC6 (0.64) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL7539554 | 0.93 | LTA4H (0.66) | HDAC6HDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL19501807 | 0.92 | HDAC4 (0.61) | HDAC6HDAC4HDAC1HDAC7HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360089-A1 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | THE UNIVERSITY OF TOLEDO (US) | 2024-10-31 | — | — | US | disclosed |
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2560690-B1 | CYCLOPENTAPEPTIDE DERIVATIVES AND USES THEREOF | Technische Universität München (DE) | 2017-03-08 | — | — | EP | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| CN-101048374-A | Mercaptoamides as histone deacetylase inhibitors | OSI PHARM INC (US) | 2007-10-03 | — | — | CN | disclosed |
| EP-1794117-A2 | MERCAPTOAMIDES AS HISTONE DEACETYLASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-26 | — | — | US | disclosed |
| US-7126001-B2 | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| WO-2006028972-A2 | MERCAPTOAMIDES AS HISTONE DEACETYLASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006028972-A2 | MERCAPTOAMIDES AS HISTONE DEACETYLASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060047123-A1 | Mercaptoamides as histone deacetylase inhibitors | AHMED SALEH | 2006-03-02 | — | — | US | disclosed |
| EP-1231919-A4 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| US-6511990-B1 | Selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-01-28 | — | — | US | disclosed |
| EP-1231919-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001018171-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360089-A1 | Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group | HDAC1, HDAC3, HDAC2 | HDAC6 9/4885HDAC4 4/4885HDAC1 1/4885 |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC6 14/4885HDAC4 6/4885HDAC1 3/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC6 14/4885HDAC4 6/4885HDAC1 3/4885 |
| US-20060047123-A1 | Mercaptoamides as histone deacetylase inhibitors | HDAC1, HDAC11, HDAC2 | HDAC6 4/4885HDAC4 12/4885HDAC1 1/4885 |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC6 12/4885HDAC4 8/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.